196 related articles for article (PubMed ID: 22683334)
21. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
[TBL] [Abstract][Full Text] [Related]
22. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H
Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232
[TBL] [Abstract][Full Text] [Related]
23. Computational approach to unravel the impact of missense mutations of proteins (D2HGDH and IDH2) causing D-2-hydroxyglutaric aciduria 2.
Thirumal Kumar D; Jerushah Emerald L; George Priya Doss C; Sneha P; Siva R; Charles Emmanuel Jebaraj W; Zayed H
Metab Brain Dis; 2018 Oct; 33(5):1699-1710. PubMed ID: 29987523
[TBL] [Abstract][Full Text] [Related]
24. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Losman JA; Looper RE; Koivunen P; Lee S; Schneider RK; McMahon C; Cowley GS; Root DE; Ebert BL; Kaelin WG
Science; 2013 Mar; 339(6127):1621-5. PubMed ID: 23393090
[TBL] [Abstract][Full Text] [Related]
25. IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.
Kranendijk M; Struys EA; van Schaftingen E; Gibson KM; Kanhai WA; van der Knaap MS; Amiel J; Buist NR; Das AM; de Klerk JB; Feigenbaum AS; Grange DK; Hofstede FC; Holme E; Kirk EP; Korman SH; Morava E; Morris A; Smeitink J; Sukhai RN; Vallance H; Jakobs C; Salomons GS
Science; 2010 Oct; 330(6002):336. PubMed ID: 20847235
[TBL] [Abstract][Full Text] [Related]
26. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
27. Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.
Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Goparaju R; Schwarzer A; Görlich K; Schottmann R; Struys EA; Jansen EE; Rohde C; Müller-Tidow C; Geffers R; Göhring G; Ganser A; Thol F; Heuser M
Leukemia; 2016 Aug; 30(8):1708-15. PubMed ID: 27063596
[TBL] [Abstract][Full Text] [Related]
28. 2-Hydroxyglutarate in Cancer Cells.
Ježek P
Antioxid Redox Signal; 2020 Nov; 33(13):903-926. PubMed ID: 31847543
[No Abstract] [Full Text] [Related]
29. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.
Terunuma A; Putluri N; Mishra P; Mathé EA; Dorsey TH; Yi M; Wallace TA; Issaq HJ; Zhou M; Killian JK; Stevenson HS; Karoly ED; Chan K; Samanta S; Prieto D; Hsu TY; Kurley SJ; Putluri V; Sonavane R; Edelman DC; Wulff J; Starks AM; Yang Y; Kittles RA; Yfantis HG; Lee DH; Ioffe OB; Schiff R; Stephens RM; Meltzer PS; Veenstra TD; Westbrook TF; Sreekumar A; Ambs S
J Clin Invest; 2014 Jan; 124(1):398-412. PubMed ID: 24316975
[TBL] [Abstract][Full Text] [Related]
30. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth.
Ma S; Jiang B; Deng W; Gu ZK; Wu FZ; Li T; Xia Y; Yang H; Ye D; Xiong Y; Guan KL
Oncotarget; 2015 Apr; 6(11):8606-20. PubMed ID: 25825982
[TBL] [Abstract][Full Text] [Related]
31. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.
Reitman ZJ; Jin G; Karoly ED; Spasojevic I; Yang J; Kinzler KW; He Y; Bigner DD; Vogelstein B; Yan H
Proc Natl Acad Sci U S A; 2011 Feb; 108(8):3270-5. PubMed ID: 21289278
[TBL] [Abstract][Full Text] [Related]
32. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
Sesanto R; Kuehn JF; Barber DL; White KA
Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
[TBL] [Abstract][Full Text] [Related]
33. Roles of the oncometabolite enantiomers of 2-hydroxyglutarate and their metabolism by diverse dehydrogenases.
Garcia I; Cornely K; Peterson CN; Berkmen MB
Essays Biochem; 2024 Jun; ():. PubMed ID: 38919140
[TBL] [Abstract][Full Text] [Related]
34. IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma.
Zhao H; Meng L; Du P; Liao X; Mo X; Gong M; Chen J; Liao Y
Biol Res; 2024 May; 57(1):30. PubMed ID: 38760850
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
[TBL] [Abstract][Full Text] [Related]
37. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Molenaar RJ; Radivoyevitch T; Maciejewski JP; van Noorden CJ; Bleeker FE
Biochim Biophys Acta; 2014 Dec; 1846(2):326-41. PubMed ID: 24880135
[TBL] [Abstract][Full Text] [Related]
38. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
[TBL] [Abstract][Full Text] [Related]
39. Abundance of d-2-hydroxyglutarate in G2/M is determined by FOXM1 in mutant IDH1-expressing cells.
Bala Bhaskara Rao K; Katragunta K; Sarma UM; Jain N
FEBS Lett; 2019 Aug; 593(16):2177-2193. PubMed ID: 31211872
[TBL] [Abstract][Full Text] [Related]
40. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
